Aa
possible good news on drug therapy
Possible good news. I was watching the Nightly Business Report on PBS last night and the stock review section had this short piece of information. A company involved in MS research had a dramatic positive jump in stock price. I don't know anything further about this but I'll share it. The part below is from the show:
Opexa Therapeutics (OPXA) - Mid- stage trials of the company's multiple sclerosis treatment showed that over 83 percent of patients remained relapse free after one year of treatment.
That would be good news if the drug trials continue to remain positive. I don't know the drug name. I know others here are great at research and can sort out the good and bad.
Cheers, Jules
Opexa Therapeutics (OPXA) - Mid- stage trials of the company's multiple sclerosis treatment showed that over 83 percent of patients remained relapse free after one year of treatment.
That would be good news if the drug trials continue to remain positive. I don't know the drug name. I know others here are great at research and can sort out the good and bad.
Cheers, Jules
sinman @ opexa therapeutics . com wouldnt let me put the email adress so i spaced it out as u can see!
My friend found me this if you have any questions to them.
They answer the next day very nice people....Easier to just ask/email directly then google for me lol
Shannon Inman
Director of Clinical Operations
Opexa Therapeutics, Inc.
2635 N Crescent Ridge Drive
The Woodlands, Texas 77381
Direct ph: 281-719-3405
Cell ph:281-889-8873
***@****
They answer the next day very nice people....Easier to just ask/email directly then google for me lol
Shannon Inman
Director of Clinical Operations
Opexa Therapeutics, Inc.
2635 N Crescent Ridge Drive
The Woodlands, Texas 77381
Direct ph: 281-719-3405
Cell ph:281-889-8873
***@****
Hey, if all goes well when would this drug be available? I've been looking around for an estimation but to no avail.
From
http://www.businesswire.com/portal/site/opexa/?ndmViewId=news_view&newsId=20090908005335&newsLang=en
"Further Analysis of TERMS Phase IIb Data Shows That 85% of Patients Treated with Tovaxin Responded Favorably, 16 % Showing Actual and Sustained Improvement in Disability "
But don't get so excited - this vaccine is for people with EARLY RRMS if it works out and gets approval.
L
http://www.businesswire.com/portal/site/opexa/?ndmViewId=news_view&newsId=20090908005335&newsLang=en
"Further Analysis of TERMS Phase IIb Data Shows That 85% of Patients Treated with Tovaxin Responded Favorably, 16 % Showing Actual and Sustained Improvement in Disability "
But don't get so excited - this vaccine is for people with EARLY RRMS if it works out and gets approval.
L
their big presentation and news conference is scheduled for Friday, Sept. 11 -
http://www.news-medical.net/news/20090908/Opexa-Therapeutics-ongoing-development-program-for-Tovaxin-to-be-presented.aspx
You can tune into it via webcast if you are interested.
http://www.news-medical.net/news/20090908/Opexa-Therapeutics-ongoing-development-program-for-Tovaxin-to-be-presented.aspx
You can tune into it via webcast if you are interested.
Jules,
Thanks for sharing this potentially exciting news - wouldn't that be great? I hope all those investors' belief in this pays off for them and us.
Lulu
Thanks for sharing this potentially exciting news - wouldn't that be great? I hope all those investors' belief in this pays off for them and us.
Lulu
Please keep me updated too!!! not good on a comp. but would love to hear anything new on this drug!! thanx so much!
Boy, I wish I had known about this BEFORE the stock rose. But as my better half says, that may also mean, (without looking it up) that the stock was worth 53 cents and went up 270%. I am going to go do some research on it now.
It sounds like this "vaccine" holds some promise. Finally something to treat the MS itself. We need to keep up with the news on this, ladies.
Jules thank you so much for posting this. Very informative.
Hugs,
Heather
It sounds like this "vaccine" holds some promise. Finally something to treat the MS itself. We need to keep up with the news on this, ladies.
Jules thank you so much for posting this. Very informative.
Hugs,
Heather
This is from Wikipedia-----------
Method of Action
Tovaxin takes a patients own T-cells from a blood sample drawn in the clinic. Attenuation of the patient's T-cells during the vaccine production process renders the cells non-replicating but viable and causes them to elicit an immune response when injected subcutaneously (under the skin) into the patient. This immune response is directed against T-cells within the patient that are self-reactive with myelin. Myelin is the sheath that covers the neurons that are affected in Multiple Sclerosis. This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients.
During the latest study treatment has consisted of four injections spaced four weeks apart followed by one injection at 24 weeks. Biannual booster shots will follow. Only minimal side effects have resulted from the use of the treatment, these consisting of mild injection site reactions, typically clearing within a day.
As any other disease modifying therapy, Tovaxin attacks the underlying cause of MS rather than just addressing its symptoms.
---------------------------------
I'll be looking for more details on the most recent results showing this 83% figure.
ess
Method of Action
Tovaxin takes a patients own T-cells from a blood sample drawn in the clinic. Attenuation of the patient's T-cells during the vaccine production process renders the cells non-replicating but viable and causes them to elicit an immune response when injected subcutaneously (under the skin) into the patient. This immune response is directed against T-cells within the patient that are self-reactive with myelin. Myelin is the sheath that covers the neurons that are affected in Multiple Sclerosis. This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients.
During the latest study treatment has consisted of four injections spaced four weeks apart followed by one injection at 24 weeks. Biannual booster shots will follow. Only minimal side effects have resulted from the use of the treatment, these consisting of mild injection site reactions, typically clearing within a day.
As any other disease modifying therapy, Tovaxin attacks the underlying cause of MS rather than just addressing its symptoms.
---------------------------------
I'll be looking for more details on the most recent results showing this 83% figure.
ess
Have an Answer?
You are reading content posted in the Multiple Sclerosis Community
Top Neurology Answerers
Australia
ON
Queensland, Australia
Queen Creek, AZ
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease
